Stock Analiz

Impact Biomedical Inc. IBO

Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026

$5.14Market cap $44M
Open the interactive analysis →

Impact Biomedical Inc. (IBO) is a healthcare company listed in the US with a market value of about $44M. In the twelve months to September 30, 2026 it had revenue of $38000 and net income of $2M, a net margin of 4247.4%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a P/E of 0.3, a 5-year average ROIC of -54%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Impact Biomedical

Impact Biomedical is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. Revenue went from $50000 in 2022 to $32000 in 2025, a decline of about 13.8% a year. It was profitable in 0 of the last 4 years in our data. Its share count fell by 55% over three years (buybacks). It spends 1062% of revenue on research and development.

Score: 1.2 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)0.3
Forward P/E—
P/FCF—
P/S1,169.0
P/B4.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-25751.9%
ROIC (5-yr avg.)-54.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 4 years

Fiscal yearTTM2025202420232022
Revenue$38000$32000——$50000
Net income$2M-$12M-$25M-$4M-$7M
Free cash flow———-$3M-$3M
EPS (diluted)$17.47$-0.38$-2.30$-0.07$-0.10
Net margin4247.4%-36993.8%——-14510.0%
ROIC—-27.9%-172.9%-8.5%-7.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Impact Biomedical’s P/E ratio?

About 0.3, based on the last twelve months of diluted earnings per share.

Is Impact Biomedical stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Impact Biomedical pay a dividend?

Not currently.

Is Impact Biomedical a good stock to buy?

We do not give buy or sell advice. Impact Biomedical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.